NCT07913100Not yet recruiting
Real-World Impact of TV-44749 in Adults With Schizophrenia
Real-World Impact of Subcutaneous Long-Acting Injectable Olanzapine Suspension (TV-44749) in Adult Patients With Schizophrenia: RADIANCE Study
Source: ClinicalTrials.gov · Last updated 3 Nov 2026
Brief summary (registry, in English)
The main purpose of this trial is to evaluate how TV-44749 (olanzapine long-acting injectable) works in routine clinical practice for adults with schizophrenia.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 1085 (estimated)
- First submitted
- 28 Oct 2026
- Start date
- 30 Mar 2027
- Primary completion date
- 31 May 2031
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Diseases
- Schizophrenia
- NCT number
- NCT07913100
What you commit to
- Study type: Observational
- Planned participants: 1085
- From 30 Mar 2027 to the primary completion date, 31 May 2031
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Established diagnosis of treatment-resistant schizophrenia, including current treatment with clozapine, clozapine treatment within the past 3-months, or treatment-resistant schizophrenia in the opinion of the investigator, as documented in the medical record
- Prior non-response to TV-44749 per clinician's judgement
- Participation in a clinical trial at the time of enrollment or within previous 6 months
Other illness
- Established current diagnosis of human immunodeficiency virus, cancers, liver failure, kidney failure, neuroleptic malignant syndrome, and diabetic ketoacidosis
- The participant has any medical or psychiatric condition that, in the opinion of the investigator, could jeopardize or would compromise the participant's ability to participate in this study
Who the study is looking for
- Adult participants with a diagnosis of schizophrenia, as per clinical judgement
- Newly prescribed or has initiated treatment with TV-44749 within the past 30 days, in accordance with the approved local label, and decided prior to and independently of participant's study participation
- Availability of at least 6 months of retrospective data prior to treatment initiation
- Written informed consent from the participant or an authorized representative able to provide written informed consent on behalf of the participant
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.